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Abstract
Aims Diabetes mellitus affects about 6% of the world’s population, and the chronic complications of the disease may result 
in macro- and micro-vascular changes. The purpose of the current study was to shed light on visual cortical oxygenation in 
diabetic individuals. We then aimed to compare the haemodynamic response (HDR) to visual stimulation with glycaemic 
control, given the likelihood of diabetic individuals suffering from such macro- and micro-vascular insult.
Methodology Thirty participants took part in this explorative study, fifteen of whom had diabetes and fifteen of whom were 
non-diabetic controls. The HDR, measured as concentrations of oxyhaemoglobin [HbO] and deoxyhaemoglobin [HbR], to 
visual stimulation was recorded over the primary visual cortex (V1) using a dual-channel oximeter. The stimulus comprised 
a pattern-reversal checkerboard presented in a block design. Participants’ mean glycated haemoglobin  (HbA1c) level (± SD) 
was 7.2 ± 0.6% in the diabetic group and 5.5 ± 0.4% in the non-diabetic group. Raw haemodynamic data were normalised 
to baseline, and the last 15 s of data from each ‘stimulus on’ and ‘stimulus off’ condition were averaged over seven duty 
cycles for each participant.
Results There were statistically significant differences in ∆[HbO] and ∆[HbR] to visual stimulation between diabetic and 
non-diabetic groups (p < 0.05). In the diabetic group, individuals with type 1 diabetes displayed an increased [HbO] (p < 0.01) 
and decreased [HbR] (p < 0.05) compared to their type 2 counterparts. There was also a linear relationship between both 
∆[HbO] and ∆[HbR] as a function of  HbA1c level (p < 0.0005).
Conclusions Our findings suggest that fNIRS can be used as a quantitative measure of cortical oxygenation in diabetes. 
Diabetic individuals have a larger HDR to visual stimulation compared to non-diabetic individuals. This increase in ∆[HbO] 
and decrease in ∆[HbR] appears to be correlated with  HbA1c level.
Keywords Haemodynamic response · Functional near-infrared spectroscopy · Visual cortex · Diabetes · Autonomic 
dysfunction
Introduction
Diabetes mellitus affects about 6% of the world’s population, 
and the chronic complications of the disease may result in 
both life- and sight-threatening macro- and micro-vascular 
insult. It is estimated that 415 million people worldwide are 
currently affected by diabetes, and this number is projected 
to increase to 642 million by 2040 [15]. Type 1 diabetes 
accounts for approximately 5–10% of cases of diabetes; type 
2 diabetes accounts for the remaining 90–95% of cases [1].
Diabetes damages not only the anatomy but also the 
physiology of the individual. Many organs are dually inner-
vated by the sympathetic (SNS) and parasympathetic (PNS) 
branches of the autonomic nervous system (ANS). It is 
well established that SNS hyperactivity occurs in systemic 
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hypertension [8, 9]. However, more recent evidence has also 
found increased SNS activity in diabetic individuals, par-
ticularly in those with type 2 diabetes [13].
Cardiovascular autonomic neuropathy (CAN) is a com-
mon complication of diabetes that is normally associated 
with dysfunction of both branches of the ANS [28]. The 
prevalence of CAN has been found to vary [7]; however, if 
patients with subclinical levels of diabetic CAN are included, 
the prevalence may in fact exceed 90% [29]. CAN has been 
found to manifest first in neurones with longer axons [28]. 
The vagus nerve is the longest nerve of the ANS, accounting 
for approximately 75% of parasympathetic innervation [12]. 
Recent evidence has found that, in many metabolic diseases, 
including diabetes, decreased vagal activity may be a key 
underlying mechanism [23, 30].
Although the aetiology of CAN is not yet fully under-
stood, several hypotheses have been purported. One such 
hypothesis is that prolonged hyperglycaemia in diabetes can 
lead to the formation of advanced glycation end products 
(AGEs) [4]. Such AGEs are seen in the glycated haemoglo-
bin  (HbA1c) test that is commonly performed on diabetic 
individuals to assess their glycaemic control.  HbA1c level 
is an indicator of blood glucose control over the preceding 
8–12 weeks. For a comprehensive review of other hypoth-
eses, please refer to Vinik et al. [30].
The haemodynamic response (HDR) is the change in 
the amount of haemoglobin in a portion of superficial cor-
tex that occurs as a reflex response to increased neuronal 
activity. It is measured by recording changes in the quan-
tity of haemoglobin in the primary visual cortex (V1) that 
occur in response to standardised visual stimulation. First 
described four decades ago [17], functional near-infrared 
spectroscopy (fNIRS) permits non-invasive measurement 
of the changes in cortical oxyhaemoglobin [HbO] and 
deoxyhaemoglobin [HbR] that comprise the HDR. Laser 
light sources are directed through the scalp and cranium 
to the cortex, and an adjacent recording ‘optode’ meas-
ures the transcranial emission of light. By selecting 687 
and 828 nm as the wavelengths of recorded light, we can 
quantify the [HbO] and [HbR] within the volume of corti-
cal tissue under observation, and disregard other poten-
tial coloured molecules. This technology is complimen-
tary to functional magnetic resonance imaging (fMRI), 
which maps out changes in metabolites and blood flow 
[10]. Unlike fMRI, which requires summation of signal 
over sustained periods of measurement, fNIRS permits the 
acquisition of data in real time; though, as with visually 
evoked cortical electrical potentials (VEP), we do average 
the response over numerous repetitions of the stimulus 
cycle.
Checkerboards are frequently used simple stimuli that 
elicit a strong response over V1 [5, 21, 25, 26, 31, 33, 35]. 
Pattern-reversal checkerboard stimulation has been found 
to produce stronger cortical activity compared to static 
checkerboards [33].
The purpose of the current study was to shed light on 
visual cortical oxygenation in diabetic individuals. We 
then aimed to compare the HDR to visual stimulation with 
glycaemic control, given the likelihood of diabetic indi-
viduals suffering from macro- and micro-vascular insult.
Methodology
Stimulus
The stimulus was a high-contrast pattern-reversal check-
erboard that was viewed binocularly at 1 m. The stimulus 
was displayed on a 19-inch monitor with a screen resolu-
tion of 800 × 600 pixels. The check size was 30 min of 
arc; recent evidence has shown that high-contrast check-
erboards with this check size produce the largest increase 
in [HbO] over the occipital cortex [31]. In accordance with 
the International Society for Clinical Electrophysiology 
of Vision (ISCEV) standards, each checkerboard had a 
temporal frequency of 7.5 Hz [22]. The stimulus utilised 
a block design. Initial baseline measures were recorded 
Fig. 1  Stimulus cycle. After baseline, participants viewed a pattern-reversal checkerboard of high contrast, which was then replaced by a grey 
screen. This was repeated seven times. (Adapted from: Ward et al. [31])
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for 60 s prior to the onset of the stimulus, whereby par-
ticipants viewed an isoluminant grey screen. Seven duty 
cycles were then presented, with each consisting of 30 s 
checkerboard stimulation (‘stimulus on’) and 30 s lumi-
nance-matched grey screen (‘stimulus off’) (Fig. 1).
Apparatus
A two-channel fNIRS oximeter (OxiplexTS, ISS, Cham-
paign, IL, USA) was used to record the HDR at occipital 
locations  O1 and  O2 over V1. The two sensors, each contain-
ing four pairs of sources and one optode, were embedded 
in silicone. This material had a degree of flexibility, which 
allowed for placement on the scalp. The sources of each 
sensor were located at fixed distances from the optode, rang-
ing from 1.9 to 3.6 cm. The intensity of the near-infrared 
(NIR) light emitted at wavelengths 687 and 828 nm was 
amplitude modulated at 110 MHz, and the sampling rate was 
1 Hz. The International 10–20 System of Electrode Place-
ment was used to locate  O1 and  O2 [16]. Each sensor was 
placed vertically such that the point that was located midway 
between the detector and farthest emitter was placed over 
the region of interest. Although recordings were made over 
left and right hemispheres, our results consider an average 
V1 response (please refer to “Effect of hemisphere” below).
Glycated haemoglobin
HbA1c was measured using the  A1cNow®+ System (PTS 
Diagnostics, Indianapolis, IN, USA), which used the princi-
ple of colourimetry. This device required a small 5 µl capil-
lary blood sample, which was obtained by means of a sin-
gle-use lancet. Upon application of the sample to the strip, 
blue micro-particles conjugated to anti-HbA1c antibodies 
migrated along the reagent strip. The amount of blue micro-
particles captured on the strip thus reflected the amount of 
 HbA1c in the sample. To determine total haemoglobin (THb) 
in the sample, the diluent converted THb to methaemoglobin 
(met-Hb). The intensity of the colour of met-Hb measured 
on the reagent strips was proportional to the concentration 
of haemoglobin in the sample. Test results were expressed 
as a percentage [i.e.,  (HbA1c/met-Hb) × 100].
Participants
We recruited thirty participants, fifteen of whom had diabe-
tes and fifteen of whom were non-diabetic controls. In the 
diabetic group, the mean age (± SD) was 47 ± 19 years, and 
the age range was 20–69 years. The male-to-female ratio 
was 8:7. The mean  HbA1c level (± SD) of the diabetic group 
was 7.2 ± 0.6%. The diabetic group comprised five individ-
uals with type 1 diabetes [mean  HbA1c level (± SD) was 
7.7 ± 0.3%] and ten individuals with type 2 diabetes [mean 
 HbA1c level (± SD) was 6.9 ± 0.6%]. The control group had 
a mean age (± SD) of 46 ± 23 years, and the age range was 
20–71 years. The male-to-female ratio was 7:8. The mean 
 HbA1c level (± SD) of the control group was 5.5 ± 0.4%. 
Both groups were matched for gender [Chi square χ2 (1, 
n = 30) = 0.133, p = 0.715] and age (Mann–Whitney U: 
U = 95, z = − 0.726, p = 0.486). At 7.2 ± 0.6% in the diabetic 
group and 5.5 ± 0.4% in the non-diabetic group, the  HbA1c 
level differed significantly between groups (independent 
samples t test: t(28) = 8.853, p < 0.0005). Furthermore, the 
 HbA1c level between individuals with type 1 and type 2 dia-
betes was significantly different [independent samples t test: 
t(13) = 2.995, p = 0.010].
Inclusion and exclusion criteria
All participants were aged 18 years or older, and had a best-
corrected visual acuity of 0.3 logMAR or better in each eye.
Participants in the diabetic group had either type 1 or 2 
diabetes mellitus, and had been diagnosed with the condition 
for at least 2 years. Furthermore, all diabetic participants 
reported no diagnosis of diabetic neuropathy (autonomic or 
peripheral).
Participants with any ocular disease (e.g., cataract, age-
related macular degeneration) or previous damage to V1 
(e.g., cerebrovascular accident, trauma) were excluded from 
the study.
Statistical methods used
The raw [HbO] and [HbR] values that were recorded from 
each participant were processed using a custom-written 
MATLAB script (MathWorks Inc., Natick, MA, USA). The 
following analyses were performed for each participant. The 
experimental data were normalised to baseline, to control for 
within-subjects’ variance. This was done by subtracting the 
mean [HbO] and [HbR] recorded during the 60 s of baseline 
prior to stimulus onset from each individual value of [HbO] 
and [HbR] recorded during stimulus presentation. A moving 
average filter was then applied to the normalised data. The 
normalised data were segmented into duty cycles of ‘stimu-
lus on’ (checkerboard) and ‘stimulus off’ condition (grey 
screen), with each ‘stimulus on’ or ‘stimulus off’ condition 
lasting 30 s. The last 15 s of data from each ‘stimulus on’ 
and ‘stimulus off’ condition were averaged over the seven 
cycles to give an average ‘stimulus on’ and ‘stimulus off’ 
condition for each participant.
Data were exported to SPSS Statistics 22 (IBM Corp., 
Armonk, NY, USA). Intraclass correlation analysis was used 
to assess for hemispheric differences in [HbO] and [HbR] 
during checkerboard and grey screen, and to assess for inter-
hemispheric differences in ∆[HbO] and ∆[HbR] between 
checkerboard and grey screen. Within- and between-group 
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analyses were conducted in SPSS Statistics 22. A three-
way mixed ANOVA was run to assess how visual stimu-
lation affected [chromophore] in diabetic and non-diabetic 
groups. We used a two-way mixed ANOVA to assess the 
∆[chromophore] to checkerboard stimulation in diabetic and 
non-diabetic groups. Multivariate linear regression was used 
to assess the ∆[chromophore] as a function of glycaemic 
control. Effect sizes are reported as partial eta-squared (ηp2) 
for ANOVA and the square of Pearson’s correlation (R2) for 
regression.
Results
Effect of hemisphere
We found a relationship between the HDRs of  O1 and  O2 
during checkerboard stimulation and grey screen using intra-
class correlation analysis. There was also a significant inter-
hemispheric relationship in the change in HDR from grey 
screen to checkerboard (i.e., ‘stimulus on’–‘stimulus off’) 
(Table 1). A two-way mixed model with average measures 
was employed. As the responses of both hemispheres were 
similar, we used an average V1 response [i.e.,  (O1 + O2)/2].
Effect of stimulation on [chromophore]
A three-way mixed ANOVA was run to understand how 
checkerboard stimulation affected [chromophore] in dia-
betic and non-diabetic groups. The within-subjects’ fac-
tors were stimulus (‘stimulus on’ or ‘stimulus off’) and 
[chromophore] ([HbO] or [HbR]); the between-subjects’ 
factor was group (diabetic or non-diabetic). There were two 
outliers for [HbR] during checkerboard stimulation in the 
non-diabetic group whose value was greater than 1.5 times 
the interquartile range (> 1.5 IQR). The mean value includ-
ing the outliers was not statistically significantly different to 
that with the outliers excluded [independent samples t test: 
t(26) = 0.962, p = 0.345]; therefore, further analysis of this 
ANOVA included the outliers. [Chromophore] was normally 
distributed in both groups during ‘stimulus on’ and ‘stimulus 
off’, as assessed by a Shapiro–Wilk test (p > 0.05).
There was a statistically significant three-way inter-
action between stimulus, [chromophore] and group 
[F(1,28) = 4.874, p = 0.036, ηp2 = 0.148]. The simple two-
way interaction between stimulus and [chromophore] 
was statistically significant in diabetic [F(1,14) = 43.394, 
p < 0.0005] and non-diabetic groups [F(1,14) = 28.733, 
p < 0.0005]. The simple two-way interaction between 
stimulus and group was statistically significant for [HbO] 
[F(1,28) = 4.426, p = 0.045] and [HbR] [F(1,28) = 5.241, 
p = 0.030].
There was a significant difference between [chromophore] 
in both diabetic [F(1,14) = 16.519, p = 0.001] and non-dia-
betic groups [F(1,14) = 38.754, p < 0.0005] during check-
erboard stimulation (Fig. 2). However, during grey screen 
presentation (‘stimulus off’), [chromophore] did not differ 
significantly in either group.
During visual stimulation, there was a statistically signifi-
cant difference in [HbO] in both diabetic [F(1,14) = 39.581, 
p < 0.0005] and non-diabetic groups [F(1,14) = 27.629, 
p < 0.0005]. In diabetic individuals, the mean (± SEM) 
[HbO] was 0.25 ± 0.16  µM during grey screen and 
1.03 ± 0.22 µM during checkerboard. In non-diabetic indi-
viduals, [HbO] was 0.24 ± 0.14 µM during grey screen and 
0.70 ± 0.11 µM during checkerboard. There was also a sta-
tistically significant difference in [HbR] in both diabetic 
[F(1,14) = 45.242, p < 0.0005] and non-diabetic groups 
[F(1,14) = 27.513, p < 0.0005] in response to visual stimu-
lation. In diabetic individuals, the mean (± SEM) [HbR] was 
0.12 ± 0.07 µM during grey screen and − 0.17 ± 0.08 µM 
during checkerboard, whereas in non-diabetic individu-
als, [HbR] was 0.02 ± 0.07 µM during grey screen and 
− 0.14 ± 0.05 µM during checkerboard stimulation.
Effect of diabetes on ∆[chromophore]
We then assessed how diabetes affected the change in 
[chromophore] (∆[chromophore]) to checkerboard stimula-
tion. We did this by means of a two-way mixed ANOVA. 
∆[Chromophore] was calculated as the difference between 
[chromophore] during checkerboard stimulation and 
[chromophore] during grey screen (i.e., ∆[HbO] = [HbO] 
checkerboard—[HbO] grey screen; ∆[HbR] = [HbR] check-
erboard—[HbR] grey screen). The within-subjects’ factor 
for this ANOVA was ∆[chromophore] (∆[HbO] or ∆[HbR]); 
the between-subjects’ factor was group (diabetic or non-
diabetic). There were no outliers in the data, as assessed by 
inspection of a boxplot for values > 1.5 IQR. ∆[Chromo-
phore] was normally distributed in both groups, as assessed 
by a Shapiro–Wilk test (p > 0.05).
There was a statistically significant two-way interac-
tion between ∆[chromophore] and group [F(1,28) = 4.874, 
p = 0.036, ηp2 = 0.148]. The main effect of ∆[chromo-
phore] was statistically significant in both diabetic 
[F(1,14) = 43.394, p < 0.0005] and non-diabetic groups 
[F(1,14) = 28.733, p < 0.0005]. Statistical significance 
Table 1  Intraclass correlation analysis between  O1 and  O2
The intraclass correlation coefficient is denoted by ρ (*p ≤ 0.05; 
**p ≤ 0.01; ***p ≤ 0.001)
Stimulus on Stimulus off ∆(On–off)
[HbO] ρ = 0.670** ρ = 0.578* ρ = 0.730***
[HbR] ρ = 0.550* ρ = 0.541* ρ = 0.612***
Acta Diabetologica 
1 3
was also found in ∆[HbO] between diabetic and non-
diabetic groups [F(1,28) = 4.426, p = 0.045]. The mean 
(± SEM) ∆[HbO] was 0.79 ± 0.11  µM in the diabetic 
group and 0.47 ± 0.11 µM in the non-diabetic group. Simi-
lar statistical significance was found in ∆[HbR] between 
groups [F(1,28) = 5.241, p = 0.030]. The mean (± SEM) 
∆[HbR] was − 0.29 ± 0.04 µM in the diabetic group and 
− 0.17 ± 0.04 µM in the non-diabetic group.
Effect of type of diabetes
We wanted to separate the effect of type of diabetes on the 
HDR. We assessed for this by means of a two-way mixed 
ANOVA in the diabetic group. The within-subjects’ factor 
for this ANOVA was ∆[chromophore] (∆[HbO] or ∆[HbR]); 
the between-subjects’ factor was type of diabetes (type 1 or 
type 2). There were no outliers in the data, as assessed by 
inspection of a boxplot for values > 1.5 IQR. ∆[Chromo-
phore] was normally distributed in both diabetic subgroups 
(type 1 and type 2), as assessed by a Shapiro–Wilk test 
(p > 0.05).
A two-way statistically significant interaction was 
found between ∆[chromophore] and type of diabetes 
[F(1,13) = 9.882, p = 0.008, ηp2 = 0.432]. The main effect 
of ∆[chromophore] was statistically significant for both 
type 1 [F(1,4) = 106.973, p < 0.0005] and type 2 subgroups 
[F(1,9) = 21.081, p = 0.001].
Statistically significant differences occurred between 
diabetic subgroups for [chromophore]. There was a statis-
tically significant difference in ∆[HbO] between the two 
subgroups [F(1,13) = 9.414, p = 0.009]. The mean (± SEM) 
∆[HbO] was 1.22 ± 0.17 µM in the type 1 subgroup and 
0.57 ± 0.12 µM in the type 2 subgroup. This pattern was 
repeated for [HbR] [F(1,13) = 7.768, p = 0.015]. The mean 
(± SEM) ∆[HbR] was − 0.43 ± 0.06 µM in the type 1 sub-
group and − 0.22 ± 0.04 µM in the type 2 subgroup (Fig. 3).
Effect of glycaemic control
Multivariate linear regression analysis was run to assess the 
effect of  HbA1c level on ∆[chromophore]. A scatterplot of 
∆[HbO] and ∆[HbR] against  HbA1c was plotted for all dia-
betic and non-diabetic participants. Visual inspection of this 
plot indicated a positive linear relationship between ∆[HbO] 
and  HbA1c. There was also a negative linear relationship 
between ∆[HbR] and  HbA1c (Fig. 4). Residuals were nor-
mally distributed, as assessed by visual inspection of a nor-
mal probability plot.
The prediction equations were as follows: ∆[HbO] = − 
1.248 + 0.297 × HbA1c; ∆[HbR] = 0.415–0.102 × HbA1c. 
 HbA1c level statistically significantly predicted ∆[HbO] 
[F(1,28) = 24.323, p < 0.0005, R2 = 0.465] and ∆[HbR] 
[F(1,28) = 21.752, p = < 0.0005, R2 = 0.437].  HbA1c 
thus accounted for 46.5% of the variation in ∆[HbO] and 
43.7% of the variation in ∆[HbR]. Both of these are large 
effect sizes [6].
Fig. 2  Normalised [chromo-
phore]
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Discussion
The purpose of this explorative study was to examine the 
differences in the HDR of diabetic individuals compared 
to non-diabetic individuals using fNIRS, given the likeli-
hood of diabetic individuals suffering from macro- or micro-
vascular insult. We found that the HDR to checkerboard 
stimulation took approximately 15 s to reach its peak, as 
has been reported in previous studies from this group [20, 
31–34]. This was true for both diabetic and non-diabetic 
individuals. For our statistical analysis, only the last 15 s of 
data from each ‘stimulus on’ and ‘stimulus off’ condition 
was used. As the responses of  O1 and  O2 were similar, our 
results considered an average V1 response.
Fig. 3  Effect of type of diabetes 
on ∆[chromophore] (*p ≤ 0.05; 
**p ≤ 0.01; ***p ≤ 0.001)
Fig. 4  Relationship between 
 HbA1c level and ∆[chromo-
phore]
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A characteristic response to visual stimulation was 
observed, with both diabetic and non-diabetic groups dis-
playing an increased [HbO] and decreased [HbR] after 
onset of the checkerboard stimulus. With neural activ-
ity, there is an overall increase in [HbO] and decrease in 
[HbR], and much more oxygen is delivered than is con-
sumed. This is a normal physiological mechanism for 
regional cerebral blood flow control, known as functional 
hyperaemia, which results in more blood flowing not only 
to the cortical locations where neurones are most active 
but also to a much larger area of cortex surrounding the 
active locations. Malonek and Grinvald [18] eloquently 
describe this phenomenon as ‘watering the entire garden 
for the sake of one thirsty flower’. Our results are in agree-
ment with the findings of previous fNIRS studies [5, 20, 
21, 25, 26, 31, 33, 35], all of which have found a similar 
functional hyperaemic response.
Diabetes is a well-established risk factor for both macro- 
and micro-vascular insult. The chronic complications of dia-
betes and vascular disease are closely intertwined in their 
pathogeneses. It is important for the relationship between 
diabetes and vascular disease to be better understood, given 
that the prevalence of diabetes is projected to continue to 
increase in the coming decades [15]. Our group analysis 
found that participants with diabetes had a significantly 
larger HDR compared to non-diabetic controls. This was 
reflected not only as an increase in delivery of arterial 
[HbO], but there was also a difference in [HbR], which is 
an indicator of venous return. Individuals with type 1 dia-
betes were found to have a larger HDR compared to those 
with type 2 diabetes. Moreover, we found a linear relation-
ship between participants’  HbA1c level and HDR, with there 
being an increase in ∆[HbO] and decrease in ∆[HbR] as a 
function of their glycaemic control.  HbA1c accounted for 
46.5% of the variation in ∆[HbO] and 43.7% of the vari-
ation in ∆[HbR], both of which are large effect sizes [6]. 
However, our results from diabetic individuals with chronic 
hyperglycaemia differ from those of an fMRI study, in which 
the authors found no substantial effect on activation of the 
occipital cortex in non-diabetic individuals with induced 
acute hyperglycaemia [11]. Perhaps the normal functioning 
of the ANS of non-diabetic individuals may be responsible 
for this. The ANS of diabetic individuals is generally chroni-
cally compromised; therefore, a short period of induced 
hyperglycaemia in non-diabetic individuals would not nec-
essarily mimic a diabetic response.
There are two hypotheses for this apparently linear rela-
tionship between HDR and glycaemic control, both of which 
involve ANS dysfunction; these are over-action of the SNS 
and under-action of the PNS. It is well established that SNS 
hyperactivity occurs in systemic hypertension [8, 9] and 
is involved in the pathogenesis of the macro- and micro-
vascular damage that ensues [19]. Systemic hypertension 
coexists in 80% of cases of type 2 diabetes and in 25% of 
cases of type 1 diabetes [3]. The presence of systemic hyper-
tension in diabetes is known to augment macro- and micro-
vascular insult [14]; even in normotensive individuals with 
type 2 diabetes, SNS activity is higher than in non-diabetic 
individuals [13]. Although SNS over-action may help us to 
understand why en bloc diabetic individuals had a higher 
HDR compared to their non-diabetic counterparts, it does 
not account for the larger HDR found in individuals with 
type 1 diabetes compared to those with type 2 diabetes.
Another hypothesis is that higher than normal arterial 
blood flow to the visual areas in response to visual stimula-
tion could be an indicator of CAN. Poor glycaemic control is 
a major risk factor for the development of CAN in diabetes 
[36]. Although it is a disorder associated with dysfunction of 
both branches of the ANS, CAN has been found to manifest 
first in neurones with longer axons [28]. The vagus nerve is 
the longest nerve of the ANS, accounting for approximately 
75% of parasympathetic innervation in the body [12]. Recent 
evidence has found that, in many metabolic diseases, includ-
ing diabetes, decreased vagal activity may be a key underly-
ing mechanism [30]. Early in the course of the disease, CAN 
tends to be associated with PNS denervation, and the SNS 
branch predominates with reduced opposition from the PNS. 
This alters the SNS–PNS tone, and a compensatory increase 
in the cardiac sympathetic tone ensues [24, 27]. Although 
we cannot prove causality, it can be hypothesised that the 
increased HDR as a function of glycaemic control may be 
due to ANS dysfunction, either by over-action of the SNS 
or under-action of the PNS.
Most diabetic individuals in this study had relatively good 
glycaemic control, in that the highest  HbA1c level recorded 
from any participant was 8.3%. Future studies should aim 
to include diabetic participants with elevated or severely 
elevated  HbA1c levels. This would be with a view to deter-
mining: (1) whether the HDR continues to increase linearly 
as a function of glycaemic control, which may suggest over-
action of the SNS; (2) whether the HDR reaches a plateau 
at given  HbA1c level; (3) whether the HDR reduces as the 
SNS branch also becomes affected in the course of CAN 
progression. In addition, other measures of autonomic activ-
ity should be included, such as heart rate and blood pressure. 
Heart rate variability would be another such measure, as 
it has been found to be directly linked to parasympathetic 
vagal activity [2]. Furthermore, in order for the results to be 
generalisable to the population, future studies should include 
many more participants from various centres.
In conclusion, our findings suggest that fNIRS can be 
used as a quantitative technique to measure cerebral oxy-
genation in diabetes. We have found that diabetic individu-
als have a larger HDR (reflected as increased ∆[HbO] and 
decreased ∆[HbR] to visual stimulation) compared to non-
diabetic individuals. These ∆[HbO] and ∆[HbR] appear to 
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be correlated with  HbA1c level. The apparently linear rela-
tionship between HDR and glycaemic control may be due 
to ANS dysfunction.
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